Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 142
- Registration Number
- NCT01798238
- Locations
- 🇰🇷
Handok Pharmaceuticals CO. LTD, Seoul, Korea, Republic of
🇰🇷Handok INC, Seoul, Gangnam-Gu, Korea, Republic of
Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals
Completed
- Conditions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 1579
- Registration Number
- NCT01753206
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Bundang-gu, Korea, Republic of
Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT01444248
- Locations
- 🇰🇷
Handok Pharmaceuticals, Seoul, Korea, Republic of
Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
Completed
- Conditions
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT01438255
- Locations
- 🇰🇷
Handok Pharmaceuticals, Seoul, Korea, Republic of
Omnaris Versus Levocetirizine Phase 4 Study
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT01430260
- Locations
- 🇰🇷
handok pharmaceuticals co. LTD, Seoul, Korea, Republic of
Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT01373398
- Locations
- 🇰🇷
Site 02, Seoul, Korea, Republic of
🇰🇷Site 01, Seoul, Korea, Republic of
Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT00975065
- Locations
- 🇰🇷
Handok Pharmaceuticals, Seoul, Korea, Republic of
Dose Proportionality Study About Amaryl M Slow Release (SR) 1/500 mg
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00934323
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00934817
Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00913367
- Locations
- 🇰🇷
HeeYoung Lee, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath